MONISTAT-DERM (miconazole nitrate) by Sight Sciences is clinical pharmacology miconazole nitrate exhibits fungicidal activity in vitro against species of the genus candida.
Drug data last refreshed 16h ago · AI intelligence enriched 1mo ago
MONISTAT-DERM (Miconazole Nitrate) is a topical antifungal lotion indicated for vulvovaginal candidiasis and other fungal infections. It exhibits fungicidal activity against Candida species through an unknown pharmacologic mechanism. The drug is absorbed minimally following topical administration with negligible systemic exposure.
Pre-launch stage with minimal commercial infrastructure; small team focused on manufacturing scale-up and regulatory readiness.
CLINICAL PHARMACOLOGY Miconazole nitrate exhibits fungicidal activity in vitro against species of the genus Candida. The pharmacologic mode of action is unknown. Following intravaginal administration of miconazole nitrate, small amounts are absorbed. Administration of a single dose of miconazole…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Prospective Two-Year Study to Assess Miconazole Nitrate Resistance in Neonates and Infants
Worked on MONISTAT-DERM at Sight Sciences? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
MONISTAT-DERM launch creates limited but focused career opportunities concentrated in manufacturing and supply chain operations. Early-stage involvement offers exposure to formulation scale-up, regulatory compliance, and operational excellence in a low-complexity topical product.
2 open roles linked to this drug